Helius Medical Technologies Sets Price for $9.1 Million Public Offering

NEWTOWN, Pa., June 04, 2025 – Helius Medical Technologies (HSDT), a neurotech firm specializing in innovative therapeutic neuromodulation for balance and gait deficiencies, has announced the pricing of its public offering. The company will offer a combined package of 2,768,600 shares of Class A common stock equivalents, coupled with warrants to purchase an additional 2,768,600 shares, setting the offering price at 3.27 dollars per share and accompanying warrants.

Each warrant included in the offering will have a lifespan of two and a half years and become immediately exercisable upon issuance. The initial exercise price is set at 7.35 dollars per share, subject to adjustments on the First and Second Reset Dates as stipulated in the warrant agreements, and also subject to a floor price. Furthermore, warrant holders have the option to exercise them on a zero-cash basis, exchanging each warrant for two common shares.

Helius anticipates gross proceeds of 9.1 million dollars before deducting fees and expenses related to the offering. The company expects the offering to close on June 6, 2025, contingent on standard closing conditions being met.

Maxim Group LLC is acting as the sole placement agent for this offering.

A registration statement on Form S-1 (File No. 333-287572) was filed with the U.S. Securities and Exchange Commission (“SEC”) and declared effective on June 4, 2025. The final prospectus, which provides full details of the offering, will be filed with the SEC and available on their website at http://www.sec.gov.

This press release is not an offer to sell, nor a solicitation of an offer to buy, any securities. Any sale of these securities will not occur in any jurisdiction where it would be unlawful prior to registration or qualification under local securities laws.

Forward-Looking Statements

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, statements regarding the completion of the public offering. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, availability of funds, and the Company’s ability to find additional sources of funding. Also included are manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company’s ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company’s ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com. The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.